SNOA Stock Analysis: Buy, Sell, or Hold?
SNOA - Sonoma Pharmaceuticals, Inc. Common Stock
$1.29
-0.15 (-10.42%)
▼
5d:
+15.18%
30d:
+2.38%
90d:
+7.5%
WAIT
LOW Confidence
Analysis Updated: Aug 10, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When SNOA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SNOA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SNOA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SNOA is currently trading at $1.29, which is considered extended relative to its 30-day fair value range of $1.13 to $1.27.
Technical Outlook: Technically, SNOA is in a strong downtrend. Immediate support is located at $1.07, while resistance sits at $1.45. Short-term momentum is weak, with the stock down 10.4% recently.
Market Sentiment: SNOA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+830.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNOA is in a strong downtrend. Immediate support is located at $1.07, while resistance sits at $1.45. Short-term momentum is weak, with the stock down 10.4% recently.
Market Sentiment: SNOA scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+830.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.13 -
$1.27
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.4%)
- BULLISH: Trading 830.2% below Wall St target ($12.00)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.13 -
$1.27
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.07
Resistance Level
$1.45
Current Trend
Strong Downtrend
Technical data as of
Aug 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.30
Wall Street Target
$12.00
(+830.2%)
Revenue Growth (YoY)
48.1%
Profit Margin
-16.3%
Share & Embed Analysis
Last updated: August 11, 2026 7:51 AM ET
Data refreshes hourly during market hours. Next update: 8:51 AM
Data refreshes hourly during market hours. Next update: 8:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNOA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$213 | 60 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$108 | 46 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 47 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$658 | 47 HOLD |
